HFS
PMCB icon

Heritage Financial Services’s PharmaCyte Biotech PMCB Stock Holding History

Heritage Financial Services’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67
Closed – – 357
2022
Q2 		$0 Buy
+67
New +$146 ﹤0.01% 531

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Heritage Financial Services's PMCB Position: Q3 2022 in Review

Heritage Financial Services sold out of PharmaCyte Biotech (PMCB) in Q3 2022, closing a stake of 67 shares.

Heritage Financial Services first reported a position in PMCB in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 31 funds tracked by Wall St. Rank hold PMCB as of Q3 2022.

  • Heritage Financial Services reported no remaining PharmaCyte Biotech position as of Q3 2022 after selling out during the quarter.
  • Heritage Financial Services sold 67 PharmaCyte Biotech shares in Q3 2022.
  • Heritage Financial Services first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 1 quarter.
  • Heritage Financial Services's PharmaCyte Biotech position peaked at $0 in Q2 2022.
  • 31 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2022.

Based on Heritage Financial Services's 13F filing for Q3 2022, filed 3 Nov 2022.